Forma Therapeutics, a developer of drugs for treating cancer, has raised $10 million in venture capital, according to a new filing by the company with the Securities and Exchange Commission. Two separate investors participated in the offering.

FORMA's novel approach to accessing high value drug targets, many of which pose significant challenges to conventional discovery approaches, leverages the integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of a novel generation of small molecule drug candidates with qualified cellular mechanisms of action. FORMA is building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics and protein-protein interactions.